Study finds metabolic biomarker signature to assist with early HNSCC detection
According to the WHO, HNSCC ranks as the seventh most common cancer and is the sixth leading cause of cancer-related mortality worldwide.
Immuno
AZD3470 at ASCO 2026: a promising new drug for Hodgkin lymphoma?
Consecutive approvals of Opdivo for Hodgkin’s lymphoma to boost sales growth
ASH 2025: Eli Lilly’s Jaypirca emerges as a strong first-line contender in CLL/SLL
ESMO 2025: potential new adjuvant option ensartinib for ALK+ NSCLC
Asbestos-related cancers still prevalent in the UK
GSK’s anti-TIM-3 antibody fails in Phase III NSCLC trial
EHA 2025: Anito-cel to disrupt CAR-T market in multiple myeloma
